Enterocolite necrosante: resposta imflamatória x corticoterapia pré-natal by Precioso, Alexander Roberto & Proença, Renata Suman Mascaretti
243
REV. HOSP. CLÍN. FAC. MED. S. PAULO 57(5):243-248, 2002SEPTEMBER-OCTOBER
From the 1Pediatric Department, Hospital
das Clínicas, Faculty of Medicine, University
of São Paulo and Experimental Unit,
Children’s Institute, Hospital das Clínicas,
Faculty of Medicine, University of São
Paulo; 2 Experimental Unit, Children’s
Institute, Hospital das Clínicas, Faculty of
Medicine, University of São Paulo and
Nursery Annexed to the Maternity Ward,
Hospital das Clínicas, Faculty of Medicine,
University of São Paulo.
NECROTIZING ENTEROCOLITIS, PATHOGENESIS
AND THE PROTECTOR EFFECT OF PRENATAL
CORTICOSTEROIDS
Alexander Roberto Precioso1 and Renata Suman Mascaretti Proença2
RHCFAP/3100
PRECIOSO AR et al. - Necrotizing enterocolitis, pathogenesis and the protector effect of prenatal corticosteroids. Rev.
Hosp. Clín. Fac. Med. S. Paulo 57(5):243-248, 2002.
Necrotizing enterocolitis is the most frequently occurring gastrointestinal disorder in premature neonates.
Animal models of necrotizing enterocolitis and prenatal administration of cortisone have demonstrated that cortisone
may accelerate maturation of the mucosal barrier, therefore reducing the incidence of this gastrointestinal disorder.
The authors present a review of the literature of the most important risk factors associated with necrotizing enterocolitis,
such as inflammatory gastrointestinal mediators, enteral feeding and bacterial colonization, and immaturity of the
gastrointestinal barrier, and we emphasize the necessity for additional studies to explore the prenatal administration of
cortisone as a preventive strategy for necrotizing enterocolitis.
DESCRIPTORS: Necrotizing enterocolitis. Neonate. Prematurity. Cortisone therapy. Physiopathology.
INTRODUCTION
Necrotizing enterocolitis (NEC) is
a common neonatal gastrointestinal
disease that affects approximately 11%
of premature neonates weighing less
than 1500 g1. The average mortality is
20% to 40%, and survivors after either
medical or surgical therapy can present
with failure to thrive, feeding abnor-
malities, diarrhea, or bowel obstruc-
tion2.
The etiology of NEC is multifac-
torial, and the most important risk fac-
tors are prematurity, hypoxia and/or
intestinal ischemia, and enteral feed-
ing and gastrointestinal bacteria colo-
nization3.
The association of such risk factors
might trigger a local inflammatory cas-
cade with release of inflammatory me-
diators, resulting in NEC4. Alterna-
tively, an imbalance between local in-
flammatory mediators and an immature
local defense could result in NEC
defense.
Early signs of NEC are indistin-
guishable from sepsis neonatorum.
The signs and symptoms are quite
variable, ranging from feeding intoler-
ance to evidence of sepsis, shock, peri-
tonitis, and death. The usual presenta-
tion includes abdominal distension,
gastric residuals, bilious vomiting, and
bloody stools. Lethargy, apnea, and
hypoperfusion also may be a promi-
nent feature. Physical findings found
on serial examination comprise pro-
gressive abdominal tenderness, muscu-
lar guarding, and abdominal wall ery-
thema. The presence of an abdominal
mass may indicate localized perfora-
tion or progressive peritoneal irritation.
However, these physical findings may
be minimal and misleading, even in
infants with progressive disease lead-
ing to perforation2.
Since prematurity is the most im-
portant risk factor associated with
NEC, possible therapeutic approaches
that promote maturation of the
gastrointestinal mucosal barrier, such
as the prenatal administration
of corticosteroids, have been explored.
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1. INTESTINAL
INFLAMMATORY MEDIATORS
Animal models of bowel necrosis
have been established by injection of
platelet-activating factor (PAF)5,6, en-
dotoxin (bacterial lipopolysaccha-
ride or LPS)5,7, and tumor necrosis fac-
tor (TNF)8. PAF has been implicated as
the most important mediator in the
pathophysiology of NEC5,.
Platelet-activating factor is a endog-
enous phospholipid mediator produced
by inflammatory cells, platelets, en-
dothelial cells, and some bacteria, such
as Escherichia coli10-14. PAF has a short
half-life in the circulation, due to the
high plasma and tissue PAF-degrading
enzyme acetylhydrolase (PAF-AH) ac-
tivity15,16, which rapidly degrades PAF
into the biologically inert lyso-PAF17.
Mesenteric or systemic administra-
tion of PAF in rats induces intestinal in-
jury similar to NEC5. On the other hand,
the administration of PAF receptor an-
tagonists in animal models of NEC in-
duced by hypoxia, endotoxin, and PAF
prevented intestinal mucosal injury7,8,18.
Considerable evidence indicates
that the altered regulation of PAF-AH
may play a role in the occurrence of
NEC because:
1) PAF-AH activity is decreased in
neonates and approaches adult en-
zyme activity only after 6 weeks of
life19,
2) PAF-AH activity is deficient in sick
neonates with NEC20,
3) PAF-AH activity can be demon-
strated in breast milk (formula has
none), and use of breast milk re-
duces the incidence of NEC21,20,
4) The administration of PAF-AH in
animal models of NEC induced by
hypoxia reduced the incidence of
NEC23.
Cundell et al.24 have demonstrated
that the PAF receptor is an important
determinant of bacterial (Streptococ-
cus) adhesion and invasion into en-
dothelium and epithelium.
Mackendrick et al.25 have found that
neonates fed enterally had higher lev-
els of PAF and endotoxin after feeding
than before feeding.
The cytotoxic effect of PAF is most
likely due to reactive oxygen radical
formation9,26-29, and its prolonged ef-
fect seems to be due to its ability to
induce TNF formation by intestine and
liver30 as well as to stimulate its own
production31.
Xanthine oxidase (XO)29,32, an en-
zyme in intestinal tissue, appears to be
the major source of free radicals in
reoxygenated tissue. Reperfusion of
the tissue supplies molecular oxygen,
which results in a burst of superoxide
radical production that damages intes-
tinal tissue by peroxidation of unsatu-
rated lipids within the cellular and mi-
tochondrial membranes.
PAF-induced bowel injury is not
only associated with production of
oxygen-derived free radicals, but also
with neutrophil margination and acti-
vation and capillary leakage33. The
importance of neutrophil cells in ini-
tiating the intestinal injury has been
demonstrated in leukopenic mice and
rats, which were relatively protected
from PAF-induced bowel injury34,35.
Nitric oxide (NO) has been demon-
strated to be a protective modulator for
the intestinal mucosa36-39. Nitric oxide
has been described as an endothelium-
derived relaxing factor that promotes
vasodilation and microvascular integrity,
inhibits leukocyte adhesion and activa-
tion, and scavenges oxygen radicals.
Nitric oxide synthase is the enzyme
responsible for NO production40. Ani-
mal models of bowel injury induced
by ischemia-reperfusion41,42, endo-
toxin43, and PAF44 have shown that in-
testinal injury is markedly exacerbated
by the concomitant inhibition of the
NO synthase. The results of these stud-
ies suggest that an imbalance between
endogenous NO and PAF production
may be the factor responsible for in-
testinal mucosal injury.
2. ENTERAL FEEDING AND
BACTERIA COLONIZATION
Enteral feeding and the pattern of
intestinal colonization and bacteria
adherence are risk factors for develop-
ing NEC and therefore have been stud-
ied by several researchers45-52.
The pattern of intestinal coloniza-
tion varies according to the type of en-
teral feeding that the neonate is receiv-
ing48. Breast feeding causes
gastrointestinal colonization predomi-
nantly by bifidobacteria (Gram-positive
bacteria), which control the growth of
Gram-negative bacteria48-52. In contrast,
formula-fed neonates are colonized pre-
dominantly by coliforms, enterococci,
and Bacteroides spp.50.
There are important differences be-
tween Gram-positive and Gram-nega-
tive bacteria regarding intestinal car-
bohydrate metabolism53. The fermen-
tation of lactose by Gram-positive bac-
teria yields lactic acid, which can be
readily absorbed from the intestinal
tract. Conversely, Gram-negative bac-
teria ferment lactose into hydrogen,
carbon dioxide, and organic acids,
which may not be cleared as readily
from the intestinal lumen.
The acidification of intraluminal
contents for a prolonged period of time
causes a reduction of local pH, which
may result in injury to the intestinal
mucosal, dissociation of divalent cati-
ons resulting in increased ionized frac-
tions, and change in the spatial configu-
ration of intraluminal proteins. These
changes in protein spatial configuration
may be able to trigger a release of va-
soactive substances that then alter in-
testinal microcirculation54,55.
Bifidobacteria release less endo-
toxin than Gram-negative bacteria; they
therefore induce the release of reduced
amounts of inflammatory mediators
such as interleukin-1, interleukin-6, and
TNF56.
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3. IMMATURITY OF THE
GASTROINTESTINAL MUCOSAL
BARRIER
The immaturity of the gastro-
intestinal mucosal barrier can be dem-
onstrated by:
1) Increased permeability of intestinal
mucosal to intact proteins57-61;
2) Reduced gastric acid secretion dur-
ing the first week of life62;
3) Reduced concentration of proteo-
lytic pancreatic enzymes63,64, enter-
okinase6, and disaccharidase and
lactase66;
4) Immaturity of gastrointestinal mo-
tor activity66,67;
5) A molar ratio of carbohydrate-to-
protein that is less in the newborn
mucus (The total protein content in
intestinal mucus from newborn rat
is greater than in adult mucus.68);
6) Structural modifications of intesti-
nal microvilli; and 69
7) Cellular and humoral gastro-
intestinal immaturity70,71.
4. PRENATAL
CORTICOSTEROIDS AND
NECROTIZING ENTEROCOLITIS
Several studies72-81 have analyzed
the maturation of intestinal mucosa
following the administration of thy-
roid hormones72-74 and steroids75-81.
Israel et al.81 have demonstrated in
an animal model that prenatal admin-
istration of corticosteroids reduces the
uptake of macromolecules from the in-
testinal mucosal82, decreases small in-
testinal bacterial colonization with
aerobic bacteria, and reduces the inci-
dence of bacterial translocation to the
liver, resulting in a lower incidence of
NEC. The association between prena-
tal administration of corticosteroids and
decreased incidence of NEC has also
been demonstrated in neonates79,83.
The effect of administration of
corticosteroids on different enzymes
has also been demonstrated77,78,80.
Buchmiller et al.80 have shown an en-
largement of the small intestine and a
trend of increasing lactase and maltase
activity after administration of
corticosteroids. Engelhardt et al.77
have demonstrated that the prenatal
administration of dexamethasone
stimulates maltase and sucrase activi-
ties; however, no effect was observed
on catalase, superoxide dismutase, and
xanthine oxidase activities. Horváth et
al.78 have shown that the prenatal ad-
ministration of betamethasone stimu-
lates Na/K – ATPase enzyme activity.
FINAL CONSIDERATIONS
The findings described above sug-
gest that the administration of prena-
tal corticosteroids is associated with
maturation of intestinal mucosal; how-
ever, further studies are necessary to
better understand the mechanisms by
which corticosteroids exert their ef-
fects.
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A enterocolite necrosante é a mais
freqüente patologia gastrointestinal
adquirida no período neonatal, acome-
tendo preferencialmente o recém-nas-
cido prematuro.
Estudos experimentais sugerem
que a corticoterapia pré-natal acelera
a maturação da mucosa gastrintestinal,
levando a diminuição da incidência
desta doença.
Os autores apresentam uma revisão
da literatura em relação aos principais
fatores fisiopatológicos associados a
enterocolite necrosante, tais como me-
diadores inflamatórios gastrintestinais,
nutrição enteral e colonização
bacteriana e imaturidade gastrintestinal
e enfatizam a necessidade de mais es-
tudos que avaliem a influencia da
corticoterapia pré-natal com fator de
prevenção da enterocolite necrosante.
DESCRITORES: Enterocolite
necrosante. Recém-nascido. Prema-
turidade. Corticoterapia. Fisiopa-
tologia.
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